Ocugen to Present Groundbreaking Therapies at BIO 2024

Ocugen

MALVERN, PAOcugen, Inc. (NASDAQ: OCGN) will present its innovative therapies at the 2024 BIO International Convention in San Diego from June 3 to June 6. The company’s leadership plans to meet potential partners and pharmaceutical executives to discuss its promising pipeline of therapies designed to address unmet medical needs.

“We are excited to return to BIO this year and showcase the significant advancements we’ve achieved both clinically and strategically,” said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. He emphasized that the convention offers a crucial platform for fostering collaborations that could advance the development of their cutting-edge treatments and increase shareholder value.

Ocugen’s modifier gene therapy platform has recently reached several critical milestones. The company initiated the OCU400 Phase 3 liMeLiGhT clinical trial for retinitis pigmentosa, a condition affecting approximately 300,000 people in the U.S. and Europe. It also completed dosing in Cohort 2 of both the OCU410 Phase 1/2 ArMaDa trial for geographic atrophy secondary to dry age-related macular degeneration, and the OCU410ST Phase 1/2 GARDian trial for Stargardt disease. These conditions affect millions globally and have limited treatment options.

A standout in Ocugen’s pipeline is NeoCart®, a Phase 3-ready regenerative cell therapy for cartilage repair. NeoCart utilizes an enhanced autologous approach that has shown the potential to fully restore cartilage in as little as six months. It’s the only therapy of its kind that uses a 3D scaffold and novel bioreactor to simulate compressive force, enhancing cartilage cell differentiation.

Ocugen’s participation in BIO 2024 is not just about showcasing their technology but also about securing partnerships that can help propel their therapies into the market. The significance of these developments lies in their potential to transform treatment paradigms for diseases with high unmet needs. For investors and stakeholders, successful collaborations could mean accelerated timelines for clinical trials and eventual commercial success.

READ:  Ocugen to Present at Oppenheimer Movers in Rare Disease Summit

The convention presentation details are as follows:

  • Event: BIO 2024 International Convention
  • Date: Monday, June 3, 2024
  • Time: 2:15 p.m. PT
  • Location: Presentation Theater 1 – Hall A – Exhibition Hall, San Diego Convention Center
  • Presenter: Dr. Shankar Musunuri

As Ocugen aims to leverage the BIO forum, the industry will be watching closely to see how these engagements might pave the way for new alliances and advancements in medical treatments.

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.